rss
J Neurol Neurosurg Psychiatry 74:1071-1079 doi:10.1136/jnnp.74.8.1071
  • Paper

Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson’s disease: a randomised, placebo controlled, double blind, six month study

  1. D J Brooks1,
  2. H Sagar2,
  3. The Uk-Irish Entacapone Study Group
  1. 1Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UK
  2. 2Department of Clinical Neurology, Royal Hallamshire Hospital, University of Sheffield, Sheffield, UK
  1. Correspondence to:
 Professor David J Brooks, MRC Cyclotron Building, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK;
 david.brooks{at}csc.mrc.ac.uk
  • Received 27 March 2002
  • Accepted 28 January 2003
  • Revised 9 September 2002

Abstract

Objective: To study the effect of entacapone, a specific peripherally acting catechol-O-methyltransferase (COMT) inhibitor used in combination with levodopa treatment, in cases of Parkinson’s disease with both fluctuating and non-fluctuating response to treatment.

Methods: A randomised, placebo controlled, double blind, six month study was undertaken in 172 fluctuating and 128 non-fluctuating patients. The clinical efficacy and safety of 200 mg entacapone given with each daily levodopa dose was studied. Efficacy was examined using home diaries, the unified Parkinson disease rating scale (UPDRS), and recording of daily levodopa dose.

Results: The primary efficacy variable for fluctuating patients—the proportion of daily ON time—showed a significant increase compared with placebo (p < 0.05). The absolute ON time (mean (SD)) increased from 9.5 (2.5) to 10.8 (2.4) hours (p < 0.01), and the daily OFF time was correspondingly reduced from 7.0 (2.6) to 5.9 (2.5) hours (p < 0.05 v placebo). This improvement was achieved despite a reduction in daily levodopa requirements. The effect was rapidly lost on withdrawal of entacapone. In non-fluctuating patients, the primary efficacy measure was part II of the UPDRS (activities of daily living; ADL). In this group of patients, ADL scores improved in the entacapone group (p < 0.01 v placebo), and there was also a 40 mg reduction in levodopa requirement (p < 0.01 v placebo). Entacapone was well tolerated by both fluctuating and non-fluctuating patients.

Conclusions: The ability of entacapone to provide additional benefits to levodopa treatment in increasing ON time in fluctuating Parkinson’s disease patients was confirmed. A novel finding was that patients without fluctuations also obtained benefit from the addition of entacapone to their levodopa treatment, as evidenced by improved ADL scores and a relatively reduced levodopa requirement.

Footnotes

  • Competing interests: DB has been reimbursed by Orion Pharma, the manufacturers of entacapone, for attending several conferences and has received honoraria. He has also served on national and international advisory boards for Orion Pharma.

Podcasts
Visit the full archive of podcasts for JNNP here >>

Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of JNNP.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article